Hydroxyethyl-Starch Solutions To Be Pulled From EU Market
Member States Can Temporarily Delay Suspension Citing Public Health Considerations
Executive Summary
Hydroxyethyl-starch solutions are being suspended from the EU following the failure of several safety measures that were introduced to prevent their use in certain high-risk patient groups.
You may also be interested in...
Rise in patient reporting boosts EU drug safety signals
The introduction of direct reporting of adverse drug reactions by patients in Europe appears to have had the desired effect: in 2013, the number of ADRs reported by patients within the European Economic Area rose by more than 50% as a result of greater public awareness of the importance of such reporting.
Italfarmaco To Seek Givinostat Approvals After Phase III Success In DMD
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.
COVID-19 Vaccine Refresh For Boosters Only? US FDA Position On Primary Series May Have Shifted
FDA advisors will vote 28 June on whether an Omicron component should be included in new COVID-19 booster vaccines. Following WHO recommendations, the FDA may no longer also be looking to update the primary vaccine series at this time.